US Stock MarketDetailed Quotes
SXTC China SXT Pharmaceuticals
- 1.0504
- -0.1096-9.45%
Close May 31 16:00 ET
- 1.0500
- -0.0004-0.04%
Post 19:59 ET
959.19KMarket Cap-38P/E (TTM)
1.1600High0.9700Low498.93KVolume1.0700Open1.1600Pre Close522.53KTurnover64.38%Turnover RatioLossP/E (Static)913.17KShares9.375052wk High0.19P/B813.97KFloat Cap0.940052wk Low--Dividend TTM774.92KShs Float46700.0000Historical High--Div YieldTTM16.38%Amplitude0.9400Historical Low1.0470Avg Price1Lot Size
China SXT Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (FY)Mar 31, 2023 | (FY)Mar 31, 2022 | (FY)Mar 31, 2021 | (FY)Mar 31, 2020 | (FY)Mar 31, 2019 | (FY)Mar 31, 2018 | (FY)Mar 31, 2017 | |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | |||||||
| Cash flow from continuing operating activities | -130.10%-80.76K | 120.38%268.29K | -240.92%-1.32M | 290.58%934.25K | -87.54%239.19K | 555.25%1.92M | 293.04K |
| Net income from continuing operations | -3.46%-5.93M | -108.72%-5.74M | 73.29%-2.75M | -768.38%-10.29M | 29.61%1.54M | 0.21%1.19M | --1.19M |
| Operating gains losses | ---- | ---- | -90.95%509K | --5.63M | ---- | ---- | ---- |
| Depreciation and amortization | -21.83%250.16K | -7.36%320.01K | 4.09%345.41K | 83.42%331.84K | 39.77%180.92K | 30.45%129.44K | --99.23K |
| Deferred tax | --0 | 270.30%328.15K | -89.42%-192.68K | -1,217.13%-101.72K | -31.99%-7.72K | ---5.85K | ---- |
| Other non cash items | -30.51%408.69K | -46.86%588.11K | -67.01%1.11M | --3.35M | ---- | ---- | ---- |
| Change In working capital | -25.62%1.42M | 218.48%1.9M | -182.52%-1.61M | 224.52%1.95M | -356.69%-1.56M | 161.43%608.99K | ---991.33K |
| -Change in receivables | 18.76%945.8K | 259.05%796.4K | -404.81%-500.72K | 111.07%164.28K | -242.73%-1.48M | 379.95%1.04M | ---371.23K |
| -Change in inventory | 326.19%408.95K | -568.14%-180.8K | -2.74%38.62K | -74.30%39.71K | 156.32%154.53K | -171.41%-274.38K | --384.22K |
| -Change in prepaid assets | -96.65%50.45K | 209.03%1.5M | -566.89%-1.38M | -640.34%-206.94K | 104.29%38.3K | -272.94%-892.32K | --515.96K |
| -Change in payables and accrued expense | -102.91%-9.62K | 941.77%330.01K | -102.08%-39.2K | 25,524.51%1.89M | -101.06%-7.42K | 143.97%703.13K | ---1.6M |
| -Change in other current liabilities | 79.38%-74.41K | -206.90%-360.86K | 282.64%337.57K | -279.14%-184.83K | -113.36%-48.75K | --365K | ---- |
| -Change in other working capital | 150.61%94.34K | -198.48%-186.4K | -125.22%-62.45K | 214.35%247.59K | 34.72%-216.52K | -521.26%-331.69K | --78.74K |
| Cash from discontinued investing activities | |||||||
| Operating cash flow | -130.10%-80.76K | 120.38%268.29K | -240.92%-1.32M | 290.58%934.25K | -87.54%239.19K | 555.25%1.92M | --293.04K |
| Investing cash flow | |||||||
| Cash flow from continuing investing activities | 73.77%-12.3K | 99.19%-46.91K | -5.62%-5.81M | -800.97%-5.5M | 41.94%-610.09K | -463.97%-1.05M | -186.31K |
| Net PPE purchase and sale | -13.11%-70.68K | 32.84%-62.49K | 77.12%-93.04K | 32.09%-406.66K | 41.85%-598.81K | -474.68%-1.03M | ---179.18K |
| Net intangibles purchase and sale | ---- | ---- | ---- | --0 | 46.37%-11.28K | -194.90%-21.03K | ---7.13K |
| Net investment purchase and sale | --0 | --0 | ---8.85M | --0 | --0 | --0 | ---- |
| Net other investing changes | 274.69%58.38K | -99.50%15.58K | 161.54%3.13M | ---5.09M | ---- | ---- | ---- |
| Cash from discontinued investing activities | |||||||
| Investing cash flow | 73.77%-12.3K | 99.19%-46.91K | -5.62%-5.81M | -800.97%-5.5M | 41.94%-610.09K | -463.97%-1.05M | ---186.31K |
| Financing cash flow | |||||||
| Cash flow from continuing financing activities | 84.41%2.94M | -87.15%1.6M | 310.32%12.41M | -66.55%3.02M | 2,977.66%9.04M | -521.47%-314.22K | -50.56K |
| Net issuance payments of debt | 44.49%4M | 2,318.39%2.77M | -101.42%-124.95K | 12,568.61%8.8M | 122.12%69.49K | -521.47%-314.22K | ---50.56K |
| Net common stock issuance | -29.54%2.19M | --3.12M | --0 | --0 | --6.49M | --0 | ---- |
| Proceeds from stock option exercised by employees | --0 | ---30K | --0 | --0 | ---- | ---- | ---- |
| Net other financing activities | 23.55%-3.26M | -134.00%-4.26M | 316.88%12.53M | -332.85%-5.78M | --2.48M | ---- | ---- |
| Cash from discontinued financing activities | |||||||
| Financing cash flow | 84.41%2.94M | -87.15%1.6M | 310.32%12.41M | -66.55%3.02M | 2,977.66%9.04M | -521.47%-314.22K | ---50.56K |
| Net cash flow | |||||||
| Beginning cash position | 16.55%15.57M | 83.33%13.36M | -21.58%7.29M | 1,312.65%9.29M | 903.15%657.77K | 473.21%65.57K | --11.44K |
| Current changes in cash | 56.81%2.85M | -65.64%1.82M | 443.76%5.29M | -117.74%-1.54M | 1,461.76%8.67M | 888.39%555.22K | --56.17K |
| Effect of exchange rate changes | -366.34%-1.05M | -49.76%394.12K | 268.06%784.54K | -1,160.84%-466.81K | -200.13%-37.02K | 1,909.94%36.98K | ---2.04K |
| End cash Position | 11.55%17.37M | 16.55%15.57M | 83.33%13.36M | -21.58%7.29M | 1,312.65%9.29M | 903.15%657.77K | --65.57K |
| Free cash flow | -173.59%-151.44K | 114.60%205.8K | -367.18%-1.41M | 242.25%527.59K | -142.66%-370.89K | 714.58%869.44K | --106.73K |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD |
| Audit Opinions | Unqualified Opinion with Explanatory Notes | Unqualified Opinion | Unqualified Opinion | Unqualified Opinion | Unqualified Opinion with Explanatory Notes | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
